Periactin

(Cyproheptadine)

ApprovedSmall molecule

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Periactin is one of 181 small molecule programs targeting Fatigue. It is currently in Approved.

Indications

Total Trials

Active Trials

180

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Mitral RegurgitationActive, not recruiting

StrokeActive, not recruiting

Abdominal PainActive, not recruiting

COVID-19Active, not recruiting

Spinal Cord InjuryActive, not recruiting

Alcohol DrinkingActive, not recruiting

GrowthActive, not recruiting

Mitral RegurgitationPhase 2

Active, not recruiting

StrokePreclinical

Active, not recruiting

Abdominal PainPhase 2

Active, not recruiting

COVID-19Phase 3

Active, not recruiting

Spinal Cord InjuryPreclinical

Active, not recruiting

Alcohol DrinkingPhase 2

Active, not recruiting

GrowthApproved

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

2 2

Bnt162b2

BioNTech

Preclinical

29 3

Singulair

AstraZeneca

Preclinical

1 4

Glucocorticoid

AbbVie

Preclinical

1 5

Calcium

Eli Lilly

Preclinical

—6

HB-Admscs

HHope Biosciences Research Foundation

Preclinical

4 7

Olokizumab

UCB

Preclinical

1 8

Conventional

PPopulation Health Research Institute

Preclinical

1 9

Selenium

SSWOG Cancer Research Network

Preclinical

1 10

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Active, not recruiting

Nausea

NCT03593811

Q3 2027

Phase 2Recruiting

Mitral Regurgitation

NCT05469165

Q3 2030

Phase 2Active, not recruiting

COVID-19

NCT04488081

Clinical

Trials by Indication[1]

COVID-192 trials

Effect of Cyproheptadine on Ventilatory Support-free Days in Critically Ill Patients With COVID-19

Unknown status·HHospital de Clinicas de Porto Alegre·Phase 3·NCT04979221·274 enrolled

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Active, not recruiting·QQuantumLeap Healthcare Collaborative·Phase 2·NCT04488081·1,500 enrolled

Pediatric2 trials

Pediatric Oncology Nutrition Intervention Trial

Completed·CCorey Hawes·Phase 2/3·NCT06175273·19 enrolled

The Use of Cyproheptadine in Pediatric Feeding Disorders

Active, not recruiting·UUniversity of Miami·Phase 4·NCT06751290·50 enrolled

Alcohol Drinking1 trial

A Study on the Biobehavioral Mechanisms of Baclofen and Alcohol Drinking

Completed·—·Phase 2·NCT01076283·14 enrolled

Growth1 trial

Effects of Cyproheptadine on Growth and Behavior in Pediatric Feeding Disorders

Terminated·MMedical College of Wisconsin·Phase 4·NCT02568007·4 enrolled

PET1 trial

Cyproheptadine as an Appetite Stimulant

Unknown status·SSt. Justine's Hospital·Phase 4·NCT01314989·20 enrolled

8 more indications

Mitral regurgitation1 trial

Serotonin Receptor Blockers in Ischemic Mitral Regurgitation

Recruiting·LLaval University·Phase 2·NCT05469165·214 enrolled

Nausea1 trial

Noninvasive Markers of Functional Nausea in Children

Active, not recruiting·VVanderbilt University Medical Center·Phase 1·NCT03593811·42 enrolled

Fatigue1 trial

Mechanisms of Neuromuscular Fatigue Post Stroke

Completed·MMedical College of Wisconsin·Phase 1·NCT01688570·27 enrolled

Combination Therapy1 trial

A Study of Combination Therapy in Children With ADHD

Completed·DDouglas Sears·Phase 4·NCT01940978·99 enrolled

Spinal Cord Injury1 trial

Molecular Markers of Neuroplasticity During Exercise in People With Incomplete Spinal Cord Injury

Completed·TT. George Hornby·N/A·NCT01538693·30 enrolled

Abdominal pain1 trial

A Placebo-controlled Crossover Trial Using Cyproheptadine To Treat Children With Functional Abdominal Pain

Terminated·UUniversity of Michigan·Phase 2·NCT01675050·4 enrolled

Stroke1 trial

Altering Activation Patterns Post-stroke

Unknown status·SShirley Ryan AbilityLab·N/A·NCT02418949·96 enrolled

Alcohol Use Disorder1 trial

Clinical Outcome of a Patented Pharmaceutical Composition (KT-110) to Treat Alcohol Use Disorder While Avoiding Major Side Effects

Completed·KKinnov Therapeutics·Phase 2·NCT04108104·154 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

PERIACTIN

NDA NDA013220

Jan 1, 1982

PERIACTIN

NDA NDA012649

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for Cyproheptadine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cyproheptadine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cyproheptadine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA013220). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Periactin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q3 2027

Q3 2030

Trials by Indication[1]

COVID-192 trials

Pediatric2 trials

Alcohol Drinking1 trial

Growth1 trial

PET1 trial

Mitral regurgitation1 trial

Nausea1 trial

Fatigue1 trial

Combination Therapy1 trial

Spinal Cord Injury1 trial

Abdominal pain1 trial

Stroke1 trial

Alcohol Use Disorder1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News